Zrivada

• Anti-HIV Agents
• Protease Inhibitors
• ATC:J05AE08

• ATV
• ATZ
• Latazanavir
• REYATAZ
• Zrivada

• No information avaliable

C₃₈H₅₂N₆O₇

http://www.rxlist.com/cgi/generic3/reyataz.htm

Zrivada FDA

No information avaliable

704.856 g/mol

No information avaliable

Free base slightly soluble (4-5 mg/mL)

Solid

4.25

Capsule (100 mg, 150 mg, or 200 mg)

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Atazanavir is rapidly absorbed with a T_max of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability

No information avaliable

Human immunodeficiency virus